IRS1 G972R polymorphism and type 2 diabetes

A paradigm for the difficult ascertainment of the contribution to disease susceptibility of 'low-frequency-low-risk' variants

E. Morini, S. Prudente, E. Succurro, M. Chandalia, Y. Y. Zhang, S. Mammarella, F. Pellegrini, C. Powers, V. Proto, B. Dallapiccola, A. Cama, G. Sesti, Nicola Abate, A. Doria, V. Trischitta

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Aims/hypothesis: The aim of the study was to determine the association between IRS1 G972R polymorphism and type 2 diabetes; published data concerning this association have been conflicting. To obtain further insight into this topic, we performed a meta-analysis of all available case-control studies. Methods: We performed a meta-analysis of 32 studies (12,076 cases and 11,285 controls). Results: The relatively infrequent R972 variant was not significantly associated with type 2 diabetes (OR 1.09, 95% CI 0.96-1.23, p∈=∈0.184 under a dominant model). Some evidence of heterogeneity was observed across studies (p∈=∈0.1). In the 14 studies (9,713 individuals) in which the mean age at type 2 diabetes diagnosis was available, this variable explained 52% of the heterogeneity (p∈=∈0.03). When these studies were subdivided into tertiles of mean age at diagnosis, the OR for diabetes was 1.48 (95% CI 1.17-1.87), 1.22 (95% CI 0.97-1.53) and 0.88 (95% CI 0.68-1.13) in the youngest, intermediate and oldest tertile, respectively (p∈=∈0.0022 for trend of ORs). Conclusions/interpretation: Our findings illustrate the difficulties of ascertaining the contribution of 'low-frequency-low-risk' variants to type 2 diabetes susceptibility. In the specific context of the R972 variant, ~200,000 study individuals would be needed to have 80% power to identify a 9% increase in diabetes risk at a genome-wide significance level. Under these circumstances, a strategy aimed at improving outcome definition and decreasing its heterogeneity may critically enhance our ability to detect genetic effects, thereby decreasing the required sample size. Our data suggest that focusing on early-onset diabetes, which is characterised by a stronger genetic background, may be part of such a strategy.

Original languageEnglish (US)
Pages (from-to)1852-1857
Number of pages6
JournalDiabetologia
Volume52
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Disease Susceptibility
Type 2 Diabetes Mellitus
Meta-Analysis
Sample Size
Case-Control Studies
Genome

Keywords

  • Age at type 2 diabetes diagnosis
  • Genetics of type 2 diabetes
  • Insulin secretion
  • Insulin signalling
  • Meta-analysis

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

IRS1 G972R polymorphism and type 2 diabetes : A paradigm for the difficult ascertainment of the contribution to disease susceptibility of 'low-frequency-low-risk' variants. / Morini, E.; Prudente, S.; Succurro, E.; Chandalia, M.; Zhang, Y. Y.; Mammarella, S.; Pellegrini, F.; Powers, C.; Proto, V.; Dallapiccola, B.; Cama, A.; Sesti, G.; Abate, Nicola; Doria, A.; Trischitta, V.

In: Diabetologia, Vol. 52, No. 9, 09.2009, p. 1852-1857.

Research output: Contribution to journalArticle

Morini, E, Prudente, S, Succurro, E, Chandalia, M, Zhang, YY, Mammarella, S, Pellegrini, F, Powers, C, Proto, V, Dallapiccola, B, Cama, A, Sesti, G, Abate, N, Doria, A & Trischitta, V 2009, 'IRS1 G972R polymorphism and type 2 diabetes: A paradigm for the difficult ascertainment of the contribution to disease susceptibility of 'low-frequency-low-risk' variants', Diabetologia, vol. 52, no. 9, pp. 1852-1857. https://doi.org/10.1007/s00125-009-1426-4
Morini, E. ; Prudente, S. ; Succurro, E. ; Chandalia, M. ; Zhang, Y. Y. ; Mammarella, S. ; Pellegrini, F. ; Powers, C. ; Proto, V. ; Dallapiccola, B. ; Cama, A. ; Sesti, G. ; Abate, Nicola ; Doria, A. ; Trischitta, V. / IRS1 G972R polymorphism and type 2 diabetes : A paradigm for the difficult ascertainment of the contribution to disease susceptibility of 'low-frequency-low-risk' variants. In: Diabetologia. 2009 ; Vol. 52, No. 9. pp. 1852-1857.
@article{1aa717081c064786b0942264fe3bd0b5,
title = "IRS1 G972R polymorphism and type 2 diabetes: A paradigm for the difficult ascertainment of the contribution to disease susceptibility of 'low-frequency-low-risk' variants",
abstract = "Aims/hypothesis: The aim of the study was to determine the association between IRS1 G972R polymorphism and type 2 diabetes; published data concerning this association have been conflicting. To obtain further insight into this topic, we performed a meta-analysis of all available case-control studies. Methods: We performed a meta-analysis of 32 studies (12,076 cases and 11,285 controls). Results: The relatively infrequent R972 variant was not significantly associated with type 2 diabetes (OR 1.09, 95{\%} CI 0.96-1.23, p∈=∈0.184 under a dominant model). Some evidence of heterogeneity was observed across studies (p∈=∈0.1). In the 14 studies (9,713 individuals) in which the mean age at type 2 diabetes diagnosis was available, this variable explained 52{\%} of the heterogeneity (p∈=∈0.03). When these studies were subdivided into tertiles of mean age at diagnosis, the OR for diabetes was 1.48 (95{\%} CI 1.17-1.87), 1.22 (95{\%} CI 0.97-1.53) and 0.88 (95{\%} CI 0.68-1.13) in the youngest, intermediate and oldest tertile, respectively (p∈=∈0.0022 for trend of ORs). Conclusions/interpretation: Our findings illustrate the difficulties of ascertaining the contribution of 'low-frequency-low-risk' variants to type 2 diabetes susceptibility. In the specific context of the R972 variant, ~200,000 study individuals would be needed to have 80{\%} power to identify a 9{\%} increase in diabetes risk at a genome-wide significance level. Under these circumstances, a strategy aimed at improving outcome definition and decreasing its heterogeneity may critically enhance our ability to detect genetic effects, thereby decreasing the required sample size. Our data suggest that focusing on early-onset diabetes, which is characterised by a stronger genetic background, may be part of such a strategy.",
keywords = "Age at type 2 diabetes diagnosis, Genetics of type 2 diabetes, Insulin secretion, Insulin signalling, Meta-analysis",
author = "E. Morini and S. Prudente and E. Succurro and M. Chandalia and Zhang, {Y. Y.} and S. Mammarella and F. Pellegrini and C. Powers and V. Proto and B. Dallapiccola and A. Cama and G. Sesti and Nicola Abate and A. Doria and V. Trischitta",
year = "2009",
month = "9",
doi = "10.1007/s00125-009-1426-4",
language = "English (US)",
volume = "52",
pages = "1852--1857",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - IRS1 G972R polymorphism and type 2 diabetes

T2 - A paradigm for the difficult ascertainment of the contribution to disease susceptibility of 'low-frequency-low-risk' variants

AU - Morini, E.

AU - Prudente, S.

AU - Succurro, E.

AU - Chandalia, M.

AU - Zhang, Y. Y.

AU - Mammarella, S.

AU - Pellegrini, F.

AU - Powers, C.

AU - Proto, V.

AU - Dallapiccola, B.

AU - Cama, A.

AU - Sesti, G.

AU - Abate, Nicola

AU - Doria, A.

AU - Trischitta, V.

PY - 2009/9

Y1 - 2009/9

N2 - Aims/hypothesis: The aim of the study was to determine the association between IRS1 G972R polymorphism and type 2 diabetes; published data concerning this association have been conflicting. To obtain further insight into this topic, we performed a meta-analysis of all available case-control studies. Methods: We performed a meta-analysis of 32 studies (12,076 cases and 11,285 controls). Results: The relatively infrequent R972 variant was not significantly associated with type 2 diabetes (OR 1.09, 95% CI 0.96-1.23, p∈=∈0.184 under a dominant model). Some evidence of heterogeneity was observed across studies (p∈=∈0.1). In the 14 studies (9,713 individuals) in which the mean age at type 2 diabetes diagnosis was available, this variable explained 52% of the heterogeneity (p∈=∈0.03). When these studies were subdivided into tertiles of mean age at diagnosis, the OR for diabetes was 1.48 (95% CI 1.17-1.87), 1.22 (95% CI 0.97-1.53) and 0.88 (95% CI 0.68-1.13) in the youngest, intermediate and oldest tertile, respectively (p∈=∈0.0022 for trend of ORs). Conclusions/interpretation: Our findings illustrate the difficulties of ascertaining the contribution of 'low-frequency-low-risk' variants to type 2 diabetes susceptibility. In the specific context of the R972 variant, ~200,000 study individuals would be needed to have 80% power to identify a 9% increase in diabetes risk at a genome-wide significance level. Under these circumstances, a strategy aimed at improving outcome definition and decreasing its heterogeneity may critically enhance our ability to detect genetic effects, thereby decreasing the required sample size. Our data suggest that focusing on early-onset diabetes, which is characterised by a stronger genetic background, may be part of such a strategy.

AB - Aims/hypothesis: The aim of the study was to determine the association between IRS1 G972R polymorphism and type 2 diabetes; published data concerning this association have been conflicting. To obtain further insight into this topic, we performed a meta-analysis of all available case-control studies. Methods: We performed a meta-analysis of 32 studies (12,076 cases and 11,285 controls). Results: The relatively infrequent R972 variant was not significantly associated with type 2 diabetes (OR 1.09, 95% CI 0.96-1.23, p∈=∈0.184 under a dominant model). Some evidence of heterogeneity was observed across studies (p∈=∈0.1). In the 14 studies (9,713 individuals) in which the mean age at type 2 diabetes diagnosis was available, this variable explained 52% of the heterogeneity (p∈=∈0.03). When these studies were subdivided into tertiles of mean age at diagnosis, the OR for diabetes was 1.48 (95% CI 1.17-1.87), 1.22 (95% CI 0.97-1.53) and 0.88 (95% CI 0.68-1.13) in the youngest, intermediate and oldest tertile, respectively (p∈=∈0.0022 for trend of ORs). Conclusions/interpretation: Our findings illustrate the difficulties of ascertaining the contribution of 'low-frequency-low-risk' variants to type 2 diabetes susceptibility. In the specific context of the R972 variant, ~200,000 study individuals would be needed to have 80% power to identify a 9% increase in diabetes risk at a genome-wide significance level. Under these circumstances, a strategy aimed at improving outcome definition and decreasing its heterogeneity may critically enhance our ability to detect genetic effects, thereby decreasing the required sample size. Our data suggest that focusing on early-onset diabetes, which is characterised by a stronger genetic background, may be part of such a strategy.

KW - Age at type 2 diabetes diagnosis

KW - Genetics of type 2 diabetes

KW - Insulin secretion

KW - Insulin signalling

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=68449104737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449104737&partnerID=8YFLogxK

U2 - 10.1007/s00125-009-1426-4

DO - 10.1007/s00125-009-1426-4

M3 - Article

VL - 52

SP - 1852

EP - 1857

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 9

ER -